Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study was to evaluate the efficacy and safety of panobinostat in
 combination with bortezomib and dexamethasone in Japanese patients with relapsed/refractory
 multiple myeloma.
Inclusion Criteria:

 -  Patient had a previous diagnosis of multiple myeloma

 -  Patient required retreatment for multiple myeloma

 -  Patient had measurable M component in serum or urine at study screening

 Exclusion Criteria:

 -  Primary refractory disease (patients that never reached at least an minor response for
 over 60 days under any prior therapy)

 -  Patient who had been treated by bortezomib before, and did not reach at least a minor
 response under this therapy, or progressed under it or within 60 days of last dose

 -  Patient received prior treatment with DAC inhibitors including panobinostat

 -  Patient had impaired cardiac function, or a prolonged QTc interval at screening ECG